Document is current

Documents that mention this clinical trial

Low myocardial energetic efficiency is associated with increased mortality in aortic stenosis
https://doi.org/10.1136/openhrt-2021-001720

High sensitivity C reactive protein as a prognostic marker in patients with mild to moderate aortic valve stenosis during lipid-lowering treatment: an SEAS substudy
https://doi.org/10.1136/openhrt-2014-000152

Higher Acceleration/Ejection Time Ratio Predicts Impaired Outcome in Aortic Valve Stenosis
https://doi.org/10.1161/circimaging.120.011467

Low systemic arterial compliance is associated with increased cardiovascular morbidity and mortality in aortic valve stenosis ^{(Post-results)}
https://doi.org/10.1136/heartjnl-2018-314386

Differences in Cardiovascular Risk Profile Between Electrocardiographic Hypertrophy Versus Strain in Asymptomatic Patients With Aortic Stenosis (from SEAS Data)
https://doi.org/10.1016/j.amjcard.2011.03.084

Prognosis in asymptomatic patients with discordantly graded aortic valve stenosis based on pressure recovery adjusted valve area
https://doi.org/10.1136/openhrt-2022-002159

Echocardiographic aortic valve calcification and outcomes in women and men with aortic stenosis
https://doi.org/10.1136/heartjnl-2016-311040

Indexing aortic valve area by body surface area increases the prevalence of severe aortic stenosis
https://doi.org/10.1136/heartjnl-2013-304443

Adjusting parameters of aortic valve stenosis severity by body size
https://doi.org/10.1136/heartjnl-2013-305225

Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: The Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study
https://doi.org/10.1016/j.ahj.2012.01.026

SuPAR predicts postoperative complications and mortality in patients with asymptomatic aortic stenosis
https://doi.org/10.1136/openhrt-2017-000743

Sex differences in cardiovascular outcome during progression of aortic valve stenosis
https://doi.org/10.1136/heartjnl-2014-306078

Effect of Randomized Lipid Lowering With Simvastatin and Ezetimibe on Cataract Development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study)
https://doi.org/10.1016/j.amjcard.2015.09.026

Velocity ratio predicts outcomes in patients with low gradient severe aortic stenosis and preserved EF
https://doi.org/10.1136/heartjnl-2014-305763

Usefulness of the Electrocardiogram in Predicting Cardiovascular Mortality in Asymptomatic Adults With Aortic Stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis Study)
https://doi.org/10.1016/j.amjcard.2014.06.006

Incidence of Cancer and Mortality in Patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Trial
https://doi.org/10.1016/j.amjcard.2014.08.016

Sudden cardiac death in asymptomatic patients with aortic stenosis
https://doi.org/10.1136/heartjnl-2019-316493

Documents that mention this clinical trial

Low myocardial energetic efficiency is associated with increased mortality in aortic stenosis
https://doi.org/10.1136/openhrt-2021-001720

High sensitivity C reactive protein as a prognostic marker in patients with mild to moderate aortic valve stenosis during lipid-lowering treatment: an SEAS substudy
https://doi.org/10.1136/openhrt-2014-000152

Higher Acceleration/Ejection Time Ratio Predicts Impaired Outcome in Aortic Valve Stenosis
https://doi.org/10.1161/circimaging.120.011467

Low systemic arterial compliance is associated with increased cardiovascular morbidity and mortality in aortic valve stenosis ^{(Post-results)}
https://doi.org/10.1136/heartjnl-2018-314386

Differences in Cardiovascular Risk Profile Between Electrocardiographic Hypertrophy Versus Strain in Asymptomatic Patients With Aortic Stenosis (from SEAS Data)
https://doi.org/10.1016/j.amjcard.2011.03.084

Prognosis in asymptomatic patients with discordantly graded aortic valve stenosis based on pressure recovery adjusted valve area
https://doi.org/10.1136/openhrt-2022-002159

Echocardiographic aortic valve calcification and outcomes in women and men with aortic stenosis
https://doi.org/10.1136/heartjnl-2016-311040

Indexing aortic valve area by body surface area increases the prevalence of severe aortic stenosis
https://doi.org/10.1136/heartjnl-2013-304443

Adjusting parameters of aortic valve stenosis severity by body size
https://doi.org/10.1136/heartjnl-2013-305225

Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: The Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study
https://doi.org/10.1016/j.ahj.2012.01.026

SuPAR predicts postoperative complications and mortality in patients with asymptomatic aortic stenosis
https://doi.org/10.1136/openhrt-2017-000743

Sex differences in cardiovascular outcome during progression of aortic valve stenosis
https://doi.org/10.1136/heartjnl-2014-306078

Effect of Randomized Lipid Lowering With Simvastatin and Ezetimibe on Cataract Development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study)
https://doi.org/10.1016/j.amjcard.2015.09.026

Velocity ratio predicts outcomes in patients with low gradient severe aortic stenosis and preserved EF
https://doi.org/10.1136/heartjnl-2014-305763

Usefulness of the Electrocardiogram in Predicting Cardiovascular Mortality in Asymptomatic Adults With Aortic Stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis Study)
https://doi.org/10.1016/j.amjcard.2014.06.006

Incidence of Cancer and Mortality in Patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Trial
https://doi.org/10.1016/j.amjcard.2014.08.016

Sudden cardiac death in asymptomatic patients with aortic stenosis
https://doi.org/10.1136/heartjnl-2019-316493